Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Bayani

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|January 7, 2015
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneityMona Meyer, Jüri Reimand, Xiaoyang Lan, et al.
NPJ Breast Cancer|June 27, 2017
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicineJane Bayani, Cindy Q Yao, Mary Anne Quintayo, et al.
NPJ Breast Cancer|July 9, 2021
Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology studyJohn M S Bartlett, Jane Bayani, Elizabeth Kornaga, et al.
Breast Cancer Research and Treatment|February 5, 2026
Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudyAndréanne Leblanc, Ana-Alicia Beltran-Bless, Gregory R Pond, et al.
Breast (Edinburgh, Scotland)|July 9, 2025
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?Ana-Alicia Beltran-Bless, Gregory R Pond, Jane Bayani, et al.
Cancer Research Communications|October 22, 2025
Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast CancerAnil Abraham Joy, Nicholas Cheng, Karen A Gelmon, et al.
Journal of the National Cancer Institute|June 20, 2018
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) TrialAntonia K Roseweir, Lindsay Bennett, Ashley Dickson, et al.
Journal of the National Cancer Institute|May 1, 2016
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the OthersJohn M S Bartlett, Jane Bayani, Andrea Marshall, et al.
Journal of Medical Internet Research|April 14, 2026
Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation StudyLisa Pilgram, Kai Yang, Ana-Alicia Beltran-Bless, et al.
Breast Cancer Research and Treatment|June 23, 2025
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozoleJudith-Anne W Chapman, Jane Bayani, Sandip SenGupta, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Proceedings of the National Academy of Sciences of the United States of America|January 7, 2015
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneityMona Meyer, Jüri Reimand, Xiaoyang Lan, et al.
NPJ Breast Cancer|June 27, 2017
Molecular stratification of early breast cancer identifies drug targets to drive stratified medicineJane Bayani, Cindy Q Yao, Mary Anne Quintayo, et al.
NPJ Breast Cancer|July 9, 2021
Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology studyJohn M S Bartlett, Jane Bayani, Elizabeth Kornaga, et al.
Breast Cancer Research and Treatment|February 5, 2026
Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudyAndréanne Leblanc, Ana-Alicia Beltran-Bless, Gregory R Pond, et al.
Breast (Edinburgh, Scotland)|July 9, 2025
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?Ana-Alicia Beltran-Bless, Gregory R Pond, Jane Bayani, et al.
Cancer Research Communications|October 22, 2025
Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast CancerAnil Abraham Joy, Nicholas Cheng, Karen A Gelmon, et al.
Journal of the National Cancer Institute|June 20, 2018
Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) TrialAntonia K Roseweir, Lindsay Bennett, Ashley Dickson, et al.
Journal of the National Cancer Institute|May 1, 2016
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the OthersJohn M S Bartlett, Jane Bayani, Andrea Marshall, et al.
Journal of Medical Internet Research|April 14, 2026
Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation StudyLisa Pilgram, Kai Yang, Ana-Alicia Beltran-Bless, et al.
Breast Cancer Research and Treatment|June 23, 2025
Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozoleJudith-Anne W Chapman, Jane Bayani, Sandip SenGupta, et al.
Pageof 9